Inotuzumab
Product Sizes
5 mg
£ POA
HY-P99264-5MG
1 mg
£ POA
HY-P99264-1MG
10 mg
£ POA
HY-P99264-10MG
25 mg
£ POA
HY-P99264-25MG
About this Product
- SKU:
- HY-P99264
- Additional Names:
- Humanized Anti-CD22 Recombinant Antibody
- Application:
- Antibody Microarray
- CAS Number:
- 1660159-36-3
- Extra Details:
- Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC); Inotuzumab ozogamicin (HY-P9959). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma[1][2][3][4].
- Molecular Weight:
- (146.48 kDa)
- Purity:
- 97.22
- References:
- [1]Aujla A, et al. Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Biomark Res. 2019 Apr 11;7:9.|[2]Wynne J, et al. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. Blood Adv. 2019 Jan 8;3(1):96-104.|[3]Kirchhoff H, et al. Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL. Blood. 2021 May 13;137(19):2657-2661.|[4]Betts AM, et al. Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin. AAPS J. 2016 Sep;18(5):1101-1116.
- Research Area:
- Cancer
- Shipping Conditions:
- Dry Ice
- Storage Conditions:
- Store at -80[o]C for 2 years
- Type:
- Antibodies
- Pathway:
- Antibody-drug Conjugate/ADC Related;Apoptosis;Immunology/Inflammation
